Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Complement System in ANCA-Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs.

Immunity, inflammation and disease·2026
Same author

Clinical Characteristics of Patients With Anti-Signal Recognition Particle Antibody: A Cohort Study.

Immunity, inflammation and disease·2026
Same author

Pneumomediastinum and Pneumopericardium in Rapidly Progressive Interstitial Lung Disease Secondary to Anti-MDA5 Dermatomyositis.

Clinical case reports·2025
Same author

Misdiagnosis of ANCA-Associated Vasculitis in Patients With Cocaine/Levamisole-Associated Autoimmune Syndrome and Cocaine-Induced Midline Destructive Lesions: A Case Series.

Immunity, inflammation and disease·2025
Same author

Age and Socioeconomic Deprivation as Key Predictors of Cardiovascular Risk in Patients With Autoimmune Rheumatic Diseases on JAK Inhibitors.

International journal of rheumatic diseases·2025
Same author

Key Determinants of Cardiovascular Outcomes in Multi-Ethnic Patients With Rheumatic Disease Using JAK Inhibitors.

Musculoskeletal care·2025

Related Experiment Video

Updated: May 27, 2025

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

13.2K

Infliximab in Autoimmune Inner Ear Disease: A Case Report.

Pauline Millan1, Kehinde O Sunmboye2

  • 1Medicine University Hospitals of Leicester NHS Trust Leicester UK.

Clinical Case Reports
|February 17, 2025
PubMed
Summary

Autoimmune inner ear disease (AIED) can cause fluctuating hearing loss. Infliximab infusions effectively managed a patient with AIED secondary to ulcerative colitis, stabilizing hearing and improving UC symptoms.

Keywords:
anti‐tumor necrosis factor alpha therapyautoimmune inner ear diseasebiologicsimmune‐mediated hearing lossinfliximab

More Related Videos

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus

Published on: February 27, 2018

8.6K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.7K

Related Experiment Videos

Last Updated: May 27, 2025

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

13.2K
A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus

Published on: February 27, 2018

8.6K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.7K

Area of Science:

  • Immunology
  • Otolaryngology
  • Gastroenterology

Background:

  • Autoimmune inner ear disease (AIED) presents as bilateral, asymmetric, fluctuating sensorineural hearing loss (SNHL).
  • Diagnosis of AIED is challenging due to a lack of standardized criteria and definitive tests.
  • Corticosteroids are the primary treatment, but long-term efficacy is limited, and post-corticosteroid treatment protocols are not well-established.

Purpose of the Study:

  • To report a case of secondary AIED in a patient with ulcerative colitis (UC).
  • To evaluate the efficacy of infliximab in managing refractory AIED and concurrent UC.
  • To highlight the potential of biologic therapy in AIED management.

Main Methods:

  • A case report of a 27-year-old male with secondary AIED and UC.
  • The patient received multiple treatments including corticosteroids, methotrexate, and azathioprine without significant improvement.
  • Treatment with infliximab infusions was initiated for both AIED and UC.

Main Results:

  • The patient experienced improvement in AIED and UC symptoms following infliximab infusions.
  • Hearing remained stable without the need for oral corticosteroids.
  • No clinical or audiometric improvement was observed with methotrexate or azathioprine.

Conclusions:

  • Infliximab demonstrated efficacy in managing a patient with AIED secondary to UC, leading to symptom improvement and hearing stabilization.
  • Biologic therapy, such as infliximab, may be a viable option for refractory AIED.
  • Further large-scale, multicenter randomized controlled trials are necessary to confirm the efficacy of biologic agents in AIED management.